RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2026

Equasens Group held its Ordinary Annual General Meeting on 25 June 2026 with a reported quorum of 87.8% and approved the separate parent company and consolidated financial statements for FY2025. The release provides voting outcomes context but does not disclose earnings figures, guidance, or changes in financial outlook. Next key dates are H1 2026 revenue on 30 July 2026 and H1 2026 results on 28 September 2026.

Analysis

The main takeaway is not the vote outcome itself but the removal of a governance overhang in a thinly traded small-cap. High participation and clean approvals usually mean less activism risk and fewer surprise corporate actions, which matters more for EQS than for larger software names because liquidity can magnify small changes in sentiment. In the near term, that should cap downside, but it does not create a fresh catalyst on its own.

The real tradable event is the July revenue update, with the September results carrying the higher information content. For a healthcare software/interop name, investors pay for recurring visibility and implementation discipline; any hint of slower deployment, weaker customer budgets, or delayed project recognition can compress the multiple quickly because the stock likely screens as a quality compounder. If revenue is merely in line, expect a drift rather than a rerate until the September print.

The contrarian risk is that the market may be assuming the sector is fully defensive when European healthcare IT budgets are not immune to procurement delays and public-sector scrutiny. The second-order effect is that misses here can trigger disproportionate selling because small-cap tech liquidity is poor, while upside is usually slower to materialize unless management upgrades full-year visibility or signals M&A. That makes the setup more suitable for event-risk management than for aggressive pre-earnings positioning.

Key Decisions for Investors

• Do not initiate a new position before the 30 Jul revenue release; use it as the first real catalyst and only engage if there is a clear reacceleration or a post-print dislocation.
• If already long EQS, keep exposure modest into the July update; trim on any sign of revenue deceleration because liquidity can gap the stock 5-10% on an in-line-to-light print.
• Buy EQS only on post-event weakness if revenue is in line and guidance is unchanged; a 5%+ selloff without a fundamental break is the preferred entry for a 1-3 month mean-reversion trade.
• For holders who need to de-risk, hedge with a short position in a broad European small-cap software/technology basket into the September results, where the information content is higher and the downside from a miss is asymmetric.
• Set a watch item on the September 28 results: if management fails to show at least stable growth visibility, the thesis shifts from defensive compounder to multiple compression, and the position should be re-underwritten.